Non-Aggression Sample Clauses

Non-Aggression. The PRINCIPALS, including the INVENTORS, shall not at any time, directly or indirectly, oppose the grant of the APPLICATIONS, nor dispute the validity or enforceability of the APPLICATIONS, nor cooperate in any suit, claim, counterclaim or defense against the APPLICATIONS, nor take the foregoing or other adverse action against any patents issuing therefrom or claiming priority to the APPLICATIONS.
Sample 1Sample 2
AutoNDA by SimpleDocs
Non-Aggression. Unless such agreement is not permitted under the law of any country, or by the precedence practice of the European Commission, LICENSEE shall not at any time, directly or indirectly, oppose the grant of, nor dispute the validity of, nor cooperate in any suit against any patent or claim included in the Patent Rights. In good faith LICENSOR has provided LICENSEE the rights and privileges contained in this Agreement. However, nothing contained in this Agreement shall be construed as (a) a warranty or representation by LICENSOR as to the validity or scope of any patent included in The Patent Rights; (b) a warranty or representation that any Licensed Product manufactured, used, leased, or sold and/or otherwise disposed of or put into use by LICENSEE will be free from infringement of patents of third CONFIDENTIAL TREATMENT REQUESTED BY DOLBY LABORATORIES, INC. parties; or (c) an agreement to defend LICENSEE against actions or suits of any nature brought by any third parties.
Sample 1
Non-Aggression. UAH shall not at any time, directly or indirectly, oppose the grant of, nor dispute the validity or enforceability of, nor cooperate in any way in any suit, claim, counterclaim or defense against any patent or claim included in the Intellectual Property.
Sample 1
Non-Aggression. Unless such agreement is not permitted under law of any country, or by precedence practice of the European Commission, LICENSEE shall require that each Sublicensee not at any time, directly or indirectly, oppose grant of, nor dispute validity of, nor cooperate in any suit against any patent or claim included in Patent Rights. In good faith LICENSORS have provided LICENSEE rights and privileges contained in this Agreement. However, nothing contained in this Agreement shall be construed as (a) warranty or representation by LICENSORS as to validity or scope of any patent included in Patent Rights; (b) warranty or representation that any Licensed Technology or Licensed Product manufactured, used, leased, or sold and/or otherwise disposed of or put into use by LICENSEE will be free from infringement of patents of third part parties, or (c) agreement to defend LICENSEE against actions or suits of any nature by any third part parties.
Sample 1
Non-Aggression. If Finisar institutes patent litigation (the “Asserting Party”) against Licensee or its Affiliates (the “Defending Party”) alleging that the Licensed Products constitutes direct or indirect patent infringement, then any covenant not to xxx granted by Licensee under this Agreement shall automatically terminate as of the date such litigation is filed.
Sample 1

Related to Non-Aggression

  • Cost Sharing a) With respect to the funding in C6.1a), should there be an amount of employee co-pay, the Trust shall advise boards what that amount shall be. Unless advised otherwise, there will be no deductions upon the Participation Date.

  • Prescription Claims against the Issuer or any Guarantor for the payment of principal or Additional Amounts, if any, on the Notes will be prescribed ten years after the applicable due date for payment thereof. Claims against the Issuer or any Guarantor for the payment of interest on the Notes will be prescribed five years after the applicable due date for payment of interest.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • HEALTH AND WELFARE 36.01 Health and welfare benefits shall be as contained in Appendix "A" of this Agreement and shall form part of this Agreement.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Virus Management Transfer Agent shall maintain a malware protection program designed to deter malware infections, detect the presence of malware within the Transfer Agent environment.

  • Subsequent Developments After the date of this Contract and until the Closing Date, Seller shall use best efforts to keep Buyer fully informed of all subsequent developments of which Seller has knowledge (“Subsequent Developments”) which would cause any of Seller’s representations or warranties contained in this Contract to be no longer accurate in any material respect.

  • Independent Development Receiving Party may currently or in the future be developing information internally, or receiving information internally, or receiving information from other parties that may be similar to the Disclosing Party's Confidential Information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Receiving Party will not develop or have developed products or services, that, without violation of this Agreement, might compete with the products or systems contemplated by the Disclosing Party's Confidential Information.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

Time is Money Join Law Insider Premium to draft better contracts faster.